Antipsychotics

Researchers point to the risks of using antipsychotics with youth and caution against the practice.

New intervention shows promise in reducing over-prescription of off-label antipsychotics in older adults.

Study finds that reduced cortical thickness and brain surface area associated with 'schizophrenia' may result from antipsychotic drug use.

Members of the U.S. Food and Drug Administration’s Psychiatry Products division go on the defensive in a new article, responding to concerns about the agency’s approval of digital aripiprazole.

A partnership designed to decrease antipsychotic use in elderly patients may have led to increased use of medications with even worse risk/benefit profiles.

With increasing evidence that psychiatric drugs do more harm than good over the long term, the field of psychiatry often seems focused on sifting through the mounds of research data it has collected, eager to at last sit up and cry, here’s a shiny speck of gold! Our drugs do work! One recently published study on withdrawal of antipsychotics tells of long-term benefits. A second tells of long-term harm. Which one is convincing?

Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.

A recent RCT showed that vitamin B6 is as effective as propranolol for the treatment of akathisia.

A new study offers radical solutions for improving the cardiovascular health of people with mental health diagnoses: reducing antipsychotic prescriptions..

A new study, published in the Journal of Clinical Psychiatry, investigates the effects of anticholinergic medications, such as antidepressants and antipsychotics, on cognition in older adults diagnosed with schizophrenia.

The researchers found that while antipsychotic drugs may be slightly more effective than alternative antidepressants, they come with a much higher side effect burden.

New research demonstrates that children diagnosed with ADHD at younger ages are more likely than those diagnosed later to receive multiple medications within five years of their diagnosis.

A new study in the journal Translational Psychiatry, an influential journal in biological psychiatry published by Nature, challenges the state of the research on antipsychotic drugs.

One-third of adults with an intellectual or developmental disability are dispensed antipsychotics, despite having no existing psychiatric diagnosis.

Large cohort study demonstrates that those with an intellectual disability are at an increased risk for movement disorder side effects of antipsychotics.

20-year follow-up study finds that after four years, patients not prescribed antipsychotics have significantly better work functioning.

A large review and meta-analysis of 167 studies across 60 years dissects placebo-controlled randomized controlled trials of antipsychotic drugs.

No placebo controlled trials provide evidence of antipsychotics in first-episode psychosis.

A large longitudinal study finds once more that being prescribed antipsychotics significantly increases the risk of diabetes.

A large observational study published in CNS Drugs sheds light on serious adverse effects of the ‘gold standard’ antipsychotic Clozapine.

Veterans diagnosed with PTSD and taking SSRIs, novel antidepressants, or atypical antipsychotics are more likely to develop dementia.

Reduced usage of antipsychotics in first-episode psychosis was associated with improved executive functioning.

Study finds that 74% of patients with a psychotic disorder off antipsychotics at end of 10 years are in remission.

Researchers recommend that healthcare professionals be vigilant regarding the signs of respiratory failure among patients with COPD who are receiving antipsychotics, especially during the initial treatment phase.

Researchers believe that side-effect monitoring is critical because of the increase in the use of antipsychotics